Eli Lilly and Company (LLY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 10,590,000 | 5,240,400 | 6,244,800 | 5,581,700 | 6,193,700 |
| Depreciation Amortization | 1,766,600 | 1,527,300 | 1,522,500 | 1,547,600 | 1,323,900 |
| Income taxes - deferred | -2,683,100 | -2,341,000 | -2,185,200 | -802,300 | -134,500 |
| Accounts receivable | -2,155,200 | -2,451,000 | -299,600 | -1,278,300 | -1,350,200 |
| Accounts payable and accrued liabilities | 2,608,800 | 4,274,400 | 1,692,000 | -1,013,800 | 1,271,300 |
| Other Working Capital | -5,385,000 | -3,055,000 | -800 | -1,012,600 | -747,400 |
| Other Operating Activity | 4,075,800 | 1,045,000 | 612,000 | 4,343,600 | -57,200 |
| Operating Cash Flow | $8,817,900 | $4,240,100 | $7,585,700 | $7,365,900 | $6,499,600 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 50,400 | 94,000 | 14,000 | -36,100 | 118,300 |
| PPE Investments | -5,057,800 | -3,447,600 | -1,854,300 | -1,309,800 | -1,387,900 |
| Net Acquisitions | -947,700 | -1,044,300 | -327,200 | -747,400 | -849,300 |
| Purchase Of Investment | -677,300 | -730,800 | -600,200 | -929,900 | -358,700 |
| Sale Of Investment | 373,600 | 508,100 | 342,200 | 800,000 | 757,100 |
| Other Investing Activity | -3,042,700 | -2,532,100 | -1,337,400 | -644,300 | -538,400 |
| Investing Cash Flow | $-9,301,500 | $-7,152,700 | $-3,762,900 | $-2,867,500 | $-2,258,900 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | -1,851,800 | 4,691,400 | 1,498,000 | N/A | -1,494,200 |
| Debt Issued | 11,417,100 | 3,958,500 | N/A | 2,406,800 | 2,062,300 |
| Debt Repayment | -664,200 | N/A | -1,560,000 | -1,905,400 | -276,500 |
| Common Stock Repurchased | -2,500,000 | -750,000 | -1,500,000 | -1,250,000 | -500,000 |
| Dividend Paid | -4,680,400 | -4,069,300 | -3,535,800 | -3,086,800 | -2,687,100 |
| Other Financing Activity | -490,600 | -335,000 | -308,900 | -295,900 | -241,600 |
| Financing Cash Flow | $1,230,100 | $3,495,600 | $-5,406,700 | $-4,131,300 | $-3,137,100 |
| Exchange Rate Effect | -296,700 | 168,600 | -167,600 | -205,700 | 216,000 |
| Beginning Cash Position | 2,818,600 | 2,067,000 | 3,818,500 | 3,657,100 | 2,337,500 |
| End Cash Position | 3,268,400 | 2,818,600 | 2,067,000 | 3,818,500 | 3,657,100 |
| Net Cash Flow | $449,800 | $751,600 | $-1,751,500 | $161,400 | $1,319,600 |
| Free Cash Flow | |||||
| Operating Cash Flow | 8,817,900 | 4,240,100 | 7,585,700 | 7,365,900 | 6,499,600 |
| Capital Expenditure | -5,057,800 | -3,447,600 | -1,854,300 | -1,309,800 | -1,387,900 |
| Free Cash Flow | 3,760,100 | 792,500 | 5,731,400 | 6,056,100 | 5,111,700 |